Page 116 - 2020年20期

rib combined with abiraterone in patients with metastatic [20] COLEMAN RL，OZA AM，LORUSSO D，et al. Rucapa-
castration-resistant prostate cancer：a randomized，dou- rib maintenance treatment for recurrent ovarian carcinoma
ble-blind，placebo-controlled，phase 2 trial[J]. Lancet On- after response to platinum therapy（ARIEL3）：a rando-
col，2018，19（7）：975-986. mized，double-blind，placebo-controlled，phase 3 trial[J].
[11] BANG YJ，XU RH，CHIN K，et al. Olaparib in combina- Lancet，2017，390（10106）：1949-1961.
tion with paclitaxel in patients with advanced gastric can- [21] MIRZA MR，MONK BJ，HERRSTEDT J，et al. Niraparib
cer who have progressed following first-line therapy maintenance therapy in platinum-sensitive，recurrent ova-
（GOLD） ：a double-blind，randomized，placebo-con- rian cancer[J]. N Engl J Med，2016，375（22）：2154-2164.
trolled，phase 3 trial[J]. Lancet Oncol，2017，18（12）： [22] OZA AM，CIBULA D，BENZAQUEN AO，et al. Olaparib
1637-1651. combined with chemotherapy for recurrent platinum-
[12] PIETANZA MC，WAQAR SN，KRUG LM，et al. Rando- sensitive ovarian cancer：a randomized phase 2 trial[J].
mized，double-blind，phase Ⅱ study of temozolomide in Lancet Oncol，2015，16（1）：87-97.
combination with either veliparib or placebo in patients [23] CERRATO A，MORRA F，CELETTI A. Use of poly
with relapsed-sensitive or refractory small-cell lung can- ADP-ribose polymerase（PARP）inhibitors in cancer cells
cer[J]. J Clin Oncol，2018，36（23）：2386-2394. bearing DDR defects：the rationale for their inclusion in
[13] LAFARGUE CJ，DALMOLIN GZ，SOOD AK，et al. Ex- the clinic[J]. J Exp Clin Cancer Res，2016. DOI：10.1186/
ploring and comparing adverse events between PARP in- s13046-016-0456-2.
hibitors[J]. Lancet Oncol，2019，20（1）：15-28. [24] EVANS T，MATULONIS U. PARP inhibitors in ovarian
[14] RUIZ-SCHUTZ VC，GOMES LM，MARIANO RC，et al. cancer：evidence，experience and clinical potential[J].
Risk of fatigue and anemia in patients with advanced can- Ther Adv Med Oncol，2017，9（4）：253-267.
cer treated with olaparib：a meta-analysis of randomized [25] ZHOU JX，FENG LJ，ZHANG X. Risk of severe hemato-
controlled trials[J]. Crit Rev Oncol Hematol，2019. DOI： logic toxicities in cancer patients treated with PARP inhib-
10.1016/j.critrevonc.2019.06.012. itors：a meta-analysis of randomized controlled trials[J].
[15] TROTTI A，COLEVAS AD，SETSER A，et al. CTCAE Drug Des Devel Ther，2017. DOI：10.2147/DDDT.
v3.0：development of a comprehensive grading system for S147726.
the adverse effects of cancer treatment[J]. Semin Radiat [26] TANGUTOORI S，BALDWIN P，SRIDHAR S. PARP in-
Oncol，2003，13（3）：176-181. hibitors：a new era of targeted therapy[J]. Maturitas，2015，
[16] 谷鸿秋，王杨，李卫. Cochrane偏倚风险评估工具在随机 81（1）：5-9.
对照研究Meta分析中的应用[J].中国循环杂志，2014，29 [27] ZHAO H，SIFAKIS EG，SUMIDA N，et al. PARP1 and
（2）：147-148. CTCF-mediated interactions between active and repressed
[17] MOORE K，COLOMBO N，SCAMBIA G，et al. Mainte- chromatin at the lamina promote oscillating transcrip-
nance olaparib in patients with newly diagnosed advanced tion[J]. Molecular Cell，2015，59（6）：984-997.
ovarian cancer[J]. N Engl J Med，2018，379（26）：2495- [28] FARRÉS J，MARTÍN-CABALLERO J，MARTÍNEZ C，
2505. et al. PARP-2 is required to maintain hematopoiesis fol-
[18] LEDERMANN J，HARTER P，GOURLEY C，et al. Olapa- lowing sublethal -irradiation in mice[J]. Blood，2013，122
rib maintenance therapy in patients with platinum-sensi- （1）：44-54.
tive relapsed serous ovarian cancer：a preplanned retro- [29] FARRÉS J，LLACUNA L，MARTIN-CABALLERO J，
spective analysis of outcomes by BRCA status in a ran- et al. PARP-2 sustains erythropoiesis in mice by limiting
domized phase 2 trial[J]. Lancet Oncol，2014，15（8）： replicative stress in erythroid progenitors[J]. Cell Death
852-861. Differ，2015，22（7）：1144-1157.
[19] PUJADE-LAURAINE E，LEDERMANN JA，SELLE F， [30] SUN QZ，GATI MI，KELLY GM. Serum-dependent and
et al. Olaparib tablets as maintenance therapy in patients independent regulation of PARP2[J]. Biochem Cell Biol，
with platinum-sensitive，relapsed ovarian cancer and a 2019，97（5）：600-611.
BRCA1/2 mutation （SOLO2/ENGOT-Ov21） ：a dou- （收稿日期：2020-05-13 修回日期：2020-08-24）
ble-blind，randomized，placebo-controlled，phase 3 trial[J]. （编辑：陈 宏）
Lancet Oncol，2017，18（9）：1274-1284.

·2538 · China Pharmacy 2020 Vol. 31 No. 20 中国药房 2020年第31卷第20期